tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

BMO sees Replimune rallying meaningfully on Prasad exit

BMO Capital analyst Evan Seigerman views the exit of Vinay Prasad, director of the FDA’s Center for Biologics Evaluation and Research, as a positive for the biopharma sector. A new director will “likely be more permissive of innovation than what we have seen to date,” the analyst tells investors in a research note. BMO expects Replimune (REPL) to rally meaningfully on the news. The stock in morning trading is up 86%, or $3.22, to $6.97 in morning trading. The firm says, however, that it remains uncertain whether Replimune’s denial of RP1 will be reconsidered with a new CBER director.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1